Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SGLT2i”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT04534270
What this trial is testing

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Who this might be right for
Proteinuria
Children's Hospital of Fudan University 23
Not applicableActive Not RecruitingNCT06813222
What this trial is testing

Anemia-Related Outcomes in Patients With CKD Treated With Dapagliflozin

Who this might be right for
AnemiaCKD
Damanhour University 100
Not applicableStudy completedNCT05402579
What this trial is testing

Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk

Who this might be right for
Diabetes Type 2DKADiabetic Ketoacidosis
Mount Sinai Hospital, Canada 63
Early research (Phase 1)Looking for participantsNCT07053306
What this trial is testing

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Who this might be right for
Type 2 Diabetes
The University of Texas Health Science Center at San Antonio 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07682350
What this trial is testing

SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial

Who this might be right for
Kidney Transplant RecipientSodium Glucose Co-Transporter 2 InhibitorsNon-Diabetic Patients+3 more
Odense University Hospital 184
Not applicableStudy completedNCT04149067
What this trial is testing

Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

Who this might be right for
Diabetes Mellitus, Type 2
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 1,080
Large-scale testing (Phase 3)Looking for participantsNCT06024746
What this trial is testing

Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Who this might be right for
Heart Failure
Colorado Prevention Center 1,500
Not applicableStudy completedNCT06902493
What this trial is testing

Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury

Who this might be right for
SepsisSeptic ShockAcute Kidney Injury
University of Jazan 664
Post-approval studies (Phase 4)Not Yet RecruitingNCT07351643
What this trial is testing

CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF

Who this might be right for
ACS (Acute Coronary Syndrome)SGLT2 Inhibitors
Shenyang Northern Hospital 110
Not applicableStudy completedNCT02993614
What this trial is testing

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

Who this might be right for
Diabetes Mellitus Type 2
AstraZeneca 99,999
Not applicableUnknownNCT03917758
What this trial is testing

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

Who this might be right for
Diabetes Mellitus, Type 2Arterial HypertensionBody Weight Changes
University of Turin, Italy 30
Not applicableLooking for participantsNCT07157475
What this trial is testing

Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

Who this might be right for
Peripheral Arterial Disease(PAD)
Wroclaw Medical University 300
Post-approval studies (Phase 4)Looking for participantsNCT06291155
What this trial is testing

Mechanism of SGLT2 Inhibition in the Kidney

Who this might be right for
Type 2 DiabetesDiabetic Kidney Disease
University of Michigan 20
Post-approval studies (Phase 4)Looking for participantsNCT07244003
What this trial is testing

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Who this might be right for
T2DM (Type 2 Diabetes Mellitus)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 430
Post-approval studies (Phase 4)Looking for participantsNCT07631156
What this trial is testing

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

Who this might be right for
Heart Failure With Reduced Ejection FractionHeart FailureVentricular Dysfunction, Left
Kyungsub Song 80
Not applicableStudy completedNCT05344963
What this trial is testing

Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors

Who this might be right for
Sodium-GLucose coTransporter-2 InhibitorsHeart Failure With Reduced Ejection Fraction
Matteo Cameli 503
Not applicableStudy completedNCT05033054
What this trial is testing

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

Who this might be right for
Kidney Disease, ChronicDiabetes
University of Texas Southwestern Medical Center 33
Large-scale testing (Phase 3)Study completedNCT03086330
What this trial is testing

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Who this might be right for
DiabetesDiabetes Mellitus, Type 2
Novo Nordisk A/S 302
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07146880
What this trial is testing

Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome

Who this might be right for
Brugada Syndrome (BrS)
National Taiwan University Hospital 10
Not applicableNot Yet RecruitingNCT07270198
What this trial is testing

Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression

Who this might be right for
Diabetic Kidney Disease (DKD)
Mario Negri Institute for Pharmacological Research 100
Next Page